ストックスクリーナーアプリを入手
48.24
3.56%
1.66
アフターアワーズ：
48.01
-0.23
-0.48%
前日終値:
$46.58
開ける：
$46.49
24時間の取引高:
2.34M
Relative Volume:
0.78
時価総額：
$9.16B
収益：
$217.77M
当期純損益:
$-438.86M
株価収益率:
-20.02
EPS:
-2.41
ネットキャッシュフロー:
$-456.33M
1週間 パフォーマンス:
+1.03%
1か月 パフォーマンス:
+3.81%
6か月 パフォーマンス:
+55.01%
1年 パフォーマンス:
+97.46%
1日の値動き範囲:
$46.28
$48.30
1週間の範囲:
$42.09
$49.77
52週間の値動き範囲:
$21.72
$49.77
Bridgebio Pharma Inc Stock (BBIO) Company Profile
BBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
48.24 | 8.57B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
638.90 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-14 | 開始されました | Jefferies | Buy |
| 2025-07-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-03 | 開始されました | Oppenheimer | Perform |
| 2024-09-04 | 開始されました | Piper Sandler | Overweight |
| 2024-03-21 | 再開されました | Raymond James | Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-07 | 開始されました | Citigroup | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-18 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-19 | 開始されました | Evercore ISI | Outperform |
| 2023-02-06 | 開始されました | Cowen | Outperform |
| 2021-12-27 | 繰り返されました | Mizuho | Buy |
| 2021-12-27 | 繰り返されました | SVB Leerink | Outperform |
| 2021-09-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-03-22 | 繰り返されました | Goldman | Buy |
| 2021-02-22 | 再開されました | JP Morgan | Overweight |
| 2021-02-09 | 再開されました | Goldman | Buy |
| 2021-01-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Neutral |
| 2020-05-19 | 開始されました | BTIG Research | Buy |
| 2020-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-19 | 開始されました | Mizuho | Buy |
| 2019-07-26 | 開始されました | Raymond James | Outperform |
| 2019-07-22 | 開始されました | BMO Capital Markets | Outperform |
| 2019-07-22 | 開始されました | Goldman | Buy |
| 2019-07-22 | 開始されました | JP Morgan | Overweight |
| 2019-07-22 | 開始されました | Jefferies | Buy |
| 2019-07-22 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Bridgebio Pharma Inc (BBIO) 最新ニュース
BridgeBio’s oncology spinout sticks with SPAC to land on Nasdaq - Endpoints News
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - 富途牛牛
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - simplywall.st
Scotiabank Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $57 to $62 - 富途牛牛
BridgeBio Pharma Shares Plunge 8.94% as $620M Trading Volume Surges 126.94% to Top 500-Stock Volume Rankings Despite $110M Revenue Growth and 3,751 Prescriptions for Attruby - AInvest
BridgeBio Pharma 2025 Q2 Earnings Deepened Losses Amid Record Revenue Growth - AInvest
BridgeBio Pharma stock hits 52-week high at 48.74 USD By Investing.com - Investing.com Australia
BridgeBio Earnings: Attruby Ramp Supports Long-Term Growth Outlook - Morningstar
BridgeBio Pharma stock rating reiterated at Buy by TD Cowen on strong Attruby sales - Investing.com Canada
As competition heats up, BridgeBio's Attruby sales underwhelm Wall Street despite growth - Endpoints News
Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share - BioPharma Dive
BridgeBio Becomes The Victim Of Its Own Success As Attruby Gathers Steam - insights.citeline.com
Bridgebio Pharma shares fall 8.86% in premarket after Q2 earnings miss and Trump's tariff announcement. - AInvest
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics - The Manila Times
BridgeBio Pharma stock price target raised to $61 by Oppenheimer - Investing.com Nigeria
Helix Acquisition Corp. II Retains Over 60% of Trust Account After Redemptions in BridgeBio Oncology Therapeutics Deal, Securing $382 Million in Gross Proceeds. - AInvest
BridgeBio Oncology Lands Massive $382M SPAC Deal as Top Investors Back Cancer Drug Pipeline - Stock Titan
BridgeBio Pharma Beat Estimates With Strong Q2 Revenue Growth - Finimize
BridgeBio Pharma Plunges 12.21% Amid Factory Orders Drop - AInvest
BridgeBio Pharma: Q2 Earnings Snapshot - New Haven Register
BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ... - Yahoo Finance
BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ... By GuruFocus - Investing.com Canada
BridgeBio Pharma Reports Strong Q2 2025 Results - TipRanks
Transcript : BridgeBio Pharma, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Earnings call transcript: BridgeBio Pharma sees revenue surge in Q2 2025 By Investing.com - Investing.com South Africa
Earnings call transcript: BridgeBio Pharma sees revenue surge in Q2 2025 - Investing.com
BridgeBio Pharma earnings missed by $0.20, revenue topped estimates - Investing.com South Africa
BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
BridgeBio Pharma, Inc. SEC 10-Q Report - TradingView
Why BridgeBio Pharma's Q2 Revenue Beat Signals a Catalyst for Outperformance - AInvest
BridgeBio Earnings: Attruby Sales Surge to $71M with Major Phase 3 Results Coming Fall 2025 - Stock Titan
BridgeBio Pharma stock hits 52-week high at 48.74 USD - Investing.com
BridgeBio Pharma Inc (BBIO) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
What makes BridgeBio Pharma Inc. stock price move sharplySkyrocketing returns - Jammu Links News
Is BridgeBio Pharma Inc. a growth stock or a value stockMaximize your returns with smart trade entries - Jammu Links News
How strong is BridgeBio Pharma Inc. company’s balance sheetConsistently high returns - Jammu Links News
Is it the right time to buy BridgeBio Pharma Inc. stockFree Stock Movement Tracking - Jammu Links News
How does BridgeBio Pharma Inc. generate profit in a changing economyBeginner Investor Watchlist For 2025 - Jammu Links News
Can volume confirm reversal in BridgeBio Pharma Inc.AI Forecast for Trending Stocks Indicates Upside - metal.it
Cantor Fitzgerald Remains a Buy on BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma Inc. stock volume spike explainedPotential Breakout Stock List Published This Week - metal.it
Raymond James assumes coverage on BridgeBio stock with Outperform rating - Investing.com Canada
BridgeBio Pharma Inc. Breaks Losing Streak — Is the Trend ReversingEarly Entry Tips With Low Risk Zone Shared - metal.it
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Cantor Fitzgerald maintains BridgeBio stock rating, sees $3B+ potential By Investing.com - Investing.com Canada
Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy - MSN
BridgeBio Pharma Inc. Hits Oversold Level on RSI IndicatorEntry Alert Based on Volume Spikes Detected - metal.it
Moving Average Crossover Confirms Uptrend in BridgeBio Pharma Inc.Stock Screener With Smart Filters Highlights Top Picks - metal.it
What is BridgeBio Pharma Inc. company’s growth strategyAchieve breakthrough performance with smart picks - Jammu Links News
Published on: 2025-07-28 13:33:40 - metal.it
Bridgebio Pharma Inc (BBIO) 財務データ
収益
当期純利益
現金流量
EPS
Bridgebio Pharma Inc (BBIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ellis Andrea | Director |
Aug 05 '25 |
Option Exercise |
16.75 |
17,167 |
287,547 |
35,756 |
| Ellis Andrea | Director |
Aug 05 '25 |
Sale |
49.00 |
17,167 |
841,183 |
18,589 |
3.70%
1.02%
大文字化:
|
ボリューム (24 時間):